For example, two recent large-scale (>200 cases) liquid biopsy studies in RCC [4,5] have deployed assays that do not include commonly mutated genes in RCC, including PBRM1, SETD2, BAP1, and KDM5C, whose mutations are associated with clinical outcomes [6]. This evidence concerns the gene PBRM1 and renal cell adenocarcinoma.